Iron carbohydrate follow-on NBCDs

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Iron carbohydrate follow-on NBCDs

Non‐Biological Complex Drugs/Reports | Posted 12/08/2016 0 Post your comment

Follow-on versions of iron–carbohydrate non-biological complex drugs (NBCDs) was a subject discussed at the International Symposium on the Scientific and Regulatory Advances in Complex Drugs, which took place in Budapest, Hungary on 27-28 October 2014 [1].

Iron–carbohydrate colloids are:
1. non-biological complex drugs;
2. carbohydrate coated polynuclear iron(III)-oxo-hydroxide cores with an unknown structure;
3. nanosized dispersions;
4. pro-drugs: highly reactive active Fe3+ to be released in a controlled manner upon administration;
5. the result of laborious, tightly controlled manufacturing processes.

Iron carbohydrate complexes are made out of different mono- or polymeric ‘sugars’, such as sucrose, gluconate, dextran, carboxymaltose, isomaltoside or polyglucosesorbitol, which stabilize the polynuclear oxyhydroxy core and affect the kinetics and (dose) tolerance of the product.

Some follow-on versions of iron-carbohydrate NBCDs have been authorized via the generics regulatory pathway (national route/decentralized procedure) without considering the consequences of their complex, colloidal/nanoparticulate structure. This is somewhat worrying when considering evidence from clinical settings, which has shown an increase in adverse drug reactions and a reduction in the efficacy of the follow-on product.

The European Medicines Agency (EMA) has issued a reflection paper for follow-on versions of iron-based nano-colloidal products in which it explains the additional data requirements for such products [2].

The approval of follow-on iron carbohydrate NBCDs (dextran derivatives) in Sweden has called into question approval on the national level, especially considering that a referral process to EMA was initiated in 2013 by the French regulatory agency for all intravenous iron products.

Conflict of interest
The authors of the conference report [1] did not provide any conflict of interest statement.

Editor’s comment
Readers interested to learn more about follow-on Iron carbohydrate NBCDs are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Retrospective chart review: disrupted anaemia control in haemodialysis patients following the switch to an iron sucrose similar (ISS) after long-term treatment with the originator iron sucrose (IS)

If you are interested in contributing a research manuscript in a similar area to the GaBI Journal, please send us your submission here.

Related articles
EU guidelines for follow-on NBCDs

Glatiramoid follow-on NBCDs

Liposomal follow-on NBCDs

Regulations for follow-on NBCDs

Status and regulatory issues surrounding follow-on NBCDs

References
1. Crommelin DJ, et al. The similarity question for biologicals and non-biological complex drugs. Eur J Pharm Sci. 2015 Aug 30;76:10-7.
2. GaBI Online - Generics and Biosimilars Initiative. EMA issues reflection paper for follow-on versions of iron-based nano-colloidal products [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 12]. Available from: www.gabionline.net/Non-Biological-Complex-Drugs/Guidelines/EMA-issues-reflection-paper-for-follow-on-versions-of-iron-based-nano-colloidal-products

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.